CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Fundamental Analysis
USA - NASDAQ:CELZ - US22529Y4089 - Common Stock
2.8 USD
-0.05 (-1.75%)
2.75 USD
-0.05 (-1.79%)
Overall CELZ gets a fundamental rating of 3 out of 10. We evaluated CELZ against 534 industry peers in the Biotechnology industry. While CELZ has a great health rating, there are worries on its profitability. CELZ is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CELZ has reported negative net income.
In the past year CELZ has reported a negative cash flow from operations.
CELZ had negative earnings in 4 of the past 5 years.
CELZ had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CELZ has a worse Return On Assets (-81.15%) than 69.10% of its industry peers.
CELZ has a Return On Equity of -84.45%. This is comparable to the rest of the industry: CELZ outperforms 50.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| ROIC | N/A |
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CELZ has a better Gross Margin (60.00%) than 78.65% of its industry peers.
CELZ's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CELZ so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
2. Health
2.1 Basic Checks
CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CELZ has more shares outstanding
CELZ has more shares outstanding than it did 5 years ago.
CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CELZ has an Altman-Z score of 0.65. This is a bad value and indicates that CELZ is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.65, CELZ is doing good in the industry, outperforming 61.98% of the companies in the same industry.
CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.65 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
CELZ has a Current Ratio of 23.89. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CELZ (23.89) is better than 96.44% of its industry peers.
CELZ has a Quick Ratio of 23.89. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 23.89, CELZ belongs to the best of the industry, outperforming 96.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 23.89 | ||
| Quick Ratio | 23.89 |
3. Growth
3.1 Past
CELZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.48%, which is quite impressive.
CELZ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -71.43%.
Measured over the past years, CELZ shows a very negative growth in Revenue. The Revenue has been decreasing by -42.17% on average per year.
EPS 1Y (TTM)21.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
Revenue 1Y (TTM)-71.43%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%-100%
3.2 Future
CELZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.08% yearly.
The Revenue is expected to grow by 544.50% on average over the next years. This is a very strong growth
EPS Next Y17.52%
EPS Next 2Y10.29%
EPS Next 3Y37.54%
EPS Next 5Y29.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y544.5%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CELZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CELZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CELZ's earnings are expected to grow with 37.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.29%
EPS Next 3Y37.54%
5. Dividend
5.1 Amount
CELZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.8
-0.05 (-1.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.78%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap7.22M
Revenue(TTM)6.00K
Net Income(TTM)-5765600
Analysts82.86
Price Target20.4 (628.57%)
Short Float %2.05%
Short Ratio1.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.59%
Min EPS beat(2)-56.49%
Max EPS beat(2)25.3%
EPS beat(4)2
Avg EPS beat(4)-22.99%
Min EPS beat(4)-74.29%
Max EPS beat(4)25.3%
EPS beat(8)3
Avg EPS beat(8)-12.91%
EPS beat(12)6
Avg EPS beat(12)-54.93%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1204 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.06 | ||
| P/tB | 1.14 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.18
EYN/A
EPS(NY)-2.91
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0
BVpS2.65
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60% | ||
| FCFM | N/A |
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 23.89 | ||
| Quick Ratio | 23.89 | ||
| Altman-Z | 0.65 |
F-Score4
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
EPS Next Y17.52%
EPS Next 2Y10.29%
EPS Next 3Y37.54%
EPS Next 5Y29.08%
Revenue 1Y (TTM)-71.43%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y544.5%
EBIT growth 1Y2.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.87%
OCF growth 3YN/A
OCF growth 5YN/A
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What is the ChartMill fundamental rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CELZ.
What is the valuation status of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
ChartMill assigns a valuation rating of 1 / 10 to CREATIVE MEDICAL TECHNOLOGY (CELZ). This can be considered as Overvalued.
How profitable is CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a profitability rating of 1 / 10.
What is the financial health of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
The financial health rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) is 7 / 10.
What is the earnings growth outlook for CREATIVE MEDICAL TECHNOLOGY?
The Earnings per Share (EPS) of CREATIVE MEDICAL TECHNOLOGY (CELZ) is expected to grow by 17.52% in the next year.